Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$314.89 USD

314.89
134,309

-1.61 (-0.51%)

Updated Nov 4, 2024 01:07 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.

LHC Group (LHCG) Q3 Earnings Match Estimates, Down Y/Y

by Zacks Equity Research

LHC Group's (LHCG) third-quarter results benefit from organic growth in both home health and hospice admissions.

Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.

Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.

Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up

by Zacks Equity Research

Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.

Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.

BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued

by Zacks Equity Research

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed

by Zacks Equity Research

Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.

STERIS (STE) Q2 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Solid growth across all three reporting segments drove STERIS' (STE) second-quarter fiscal 2022 revenues.

    QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up

    by Zacks Equity Research

    QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.

    Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up

    by Zacks Equity Research

    Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.

    Tandem Diabetes (TNDM) Q3 Earnings Top Estimates, Sales View Up

    by Zacks Equity Research

    Tandem Diabetes (TNDM) reports better-than-expected revenues for third-quarter 2021 as strong domestic and international pump shipments drive the top line.

      AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

      by Zacks Equity Research

      AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.

      DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

      by Zacks Equity Research

      DENTSPLY SIRONA's (XRAY) third-quarter results benefit from strong segmental performance.

      Change Healthcare (CHNG) Q2 Earnings Beat, Revenues Miss

      by Zacks Equity Research

      Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance across Software and Analytics and Network Solutions segments.

      Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View

      by Zacks Equity Research

      Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.

      Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up

      by Zacks Equity Research

      Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.

      Avanos Medical (AVNS) Q3 Earnings Lag Estimates, Revenues Top

      by Zacks Equity Research

      Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.

      Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track

      by Zacks Equity Research

      An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.

      Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up

      by Zacks Equity Research

      Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.

      Fresenius Medical (FMS) Q3 Earnings Beat Estimates, Down Y/Y

      by Zacks Equity Research

      Fresenius Medical's (FMS) third-quarter earnings benefit from strong performance across the regions, Asia Pacific and Latin America.

      PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

      by Zacks Equity Research

      PerkinElmer's (PKI) third-quarter results benefit from strong segmental performance.

      CVS Health (CVS) Q3 Earnings Top Estimates, 2021 EPS View Up

      by Zacks Equity Research

      Strength in all three operating segments drove CVS Health's (CVS) revenues in the third quarter of 2021.